Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377616 | 0.84 | GAA (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12379061 | 0.82 | ALDH1A1 (0.37) | ALDH1A1HTTSMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL12379055 | 0.77 | KDM4E (0.34) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12379054 | 0.76 | HTT (0.34) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12379052 | 0.75 | NPC1 (0.49) | ALDH1A1HTT | |
| SCHEMBL4248562 | 0.74 | GAA (0.44) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12379047 | 0.74 | MMP1 (0.37) | ALDH1A1HTT | |
| SCHEMBL4245845 | 0.73 | GYS1 (0.34) | SMN1; SMN2 | |
| SCHEMBL17689585 | 0.69 | MAOA (0.37) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4240861 | 0.68 | HPGD (0.50) | ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7956010-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100048701-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | NAT1, AGXT, HAX1 | ALDH1A1 2983/4885HTT 4158/4885SMN1; SMN2 3408/4885 |
| US-20100048701-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | ALDH1A1 2614/4885HTT 3034/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.